Pfizer stock may not be as hyped as the COVID-19 business looks to wind down. However, with a renewed growth strategy, PFE stock can offer investors growth at a value price.
Shares of COVID vaccine maker Pfizer (PFE) are steadily trending higher again.The $300 billion biopharmaceutical company doesn’t get nearly as much press as it did a few years ago. Undoubtedly, Pfizer was met with much praise following the miraculous marvel that’s since been taken for granted.
Even as the COVID-19 business winds down, Pfizer remains one of this market’s most innovative companies and the 12.3 times trailing earnings multiple does not do its justice.
With a new growth mindset and investment in other intriguing businesses, Pfizer stock seems eager to prove it’s worthy of a much higher multiple. With a stellar management team and discounted growth capabilities, stock attempts to revisit its highs near $60 per share.
